Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.56 |
| ▸ | HRH1 | P35367 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | HTR2B | P41595 | 3/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1152486 | 1.00 | LMNA (0.56) | LMNAOPRM1HIF1AMEN1KMT2A | |
| SCHEMBL1152798 | 0.94 | LMNA (0.51) | LMNAOPRM1HIF1AMEN1KMT2A | |
| SCHEMBL1152796 | 0.94 | LMNA (0.51) | LMNAOPRM1HIF1AMEN1KMT2A | |
| Fumaric Acid SCHEMBL9809236 | 0.92 | LMNA (0.51) | LMNAOPRM1HIF1AMEN1KMT2A | |
| Fumaric Acid SCHEMBL9809238 | 0.92 | LMNA (0.51) | LMNAOPRM1HIF1AMEN1KMT2A | |
| Fumaric Acid SCHEMBL9809232 | 0.92 | LMNA (0.51) | LMNAOPRM1HIF1AMEN1KMT2A | |
| SCHEMBL1151668 | 0.89 | LMNA (0.57) | LMNAOPRM1HIF1AMEN1KMT2A | |
| SCHEMBL1151665 | 0.89 | LMNA (0.57) | LMNAOPRM1HIF1AMEN1KMT2A | |
| SCHEMBL1152474 | 0.84 | LMNA (0.64) | LMNAOPRM1HIF1AMEN1KMT2A | |
| SCHEMBL1152476 | 0.84 | LMNA (0.64) | LMNAOPRM1HIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0187639-B1 | NOVEL PIPERAZINE DERIVATIVES, PROCESSES FOR PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AS ACTIVE INGREDIENT | KANEBO, LTD. (JP) | 1991-05-02 | — | — | EP | claimed |
| US-4703048-A | Novel 1-benzhydryl-4-cinnamylpiperazine derivatives, and pharmaceutical compositions comprising said compounds as active ingredient for treating a cerebrovascular disease | KANEBO LTD. (JP) | 1987-10-27 | — | — | US | claimed |
| EP-0187639-A1 | Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient | KANEBO, LTD. (JP) | 1986-07-16 | — | — | EP | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| EP-0187639-B1 | NOVEL PIPERAZINE DERIVATIVES, PROCESSES FOR PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AS ACTIVE INGREDIENT | KANEBO, LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| US-4703048-A | Novel 1-benzhydryl-4-cinnamylpiperazine derivatives, and pharmaceutical compositions comprising said compounds as active ingredient for treating a cerebrovascular disease | KANEBO LTD. (JP) | 1987-10-27 | — | — | US | disclosed |
| EP-0187639-A1 | Novel piperazine derivatives, processes for production thereof, and pharmaceutical compositions comprising said compounds as active ingredient | KANEBO, LTD. (JP) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | LMNA 156/4885OPRM1 3829/4885HIF1A 1389/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | LMNA 156/4885OPRM1 3829/4885HIF1A 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.